Seroquel Time-Release Profile
Seroquel XR (extended-release quetiapine) is formulated to release medication over approximately 24 hours, reaching peak plasma concentration (Tmax) at approximately 5-6 hours after administration, compared to 1.5-2 hours for immediate-release formulations 1.
Pharmacokinetic Characteristics
Extended-Release (Seroquel XR) Formulation
- Time to peak concentration (Tmax): 5-6 hours after oral administration 2
- Elimination half-life: Approximately 7 hours for quetiapine and 18 hours for the active metabolite N-desalkyl quetiapine (norquetiapine) 3
- Steady-state: Achieved within 2-3 days of consecutive dosing 3, 4
- Duration of action: Designed for once-daily dosing with 24-hour coverage 4, 2
The extended-release formulation provides more consistent plasma levels throughout the day compared to immediate-release quetiapine, with less pronounced peak-to-trough fluctuations 4. The coefficient of variation for total daily exposure (AUC) is lower with XR (39.2%) versus immediate-release (51.2%), indicating more predictable pharmacokinetics 4.
Immediate-Release (Seroquel IR) Formulation
For comparison, the immediate-release formulation:
- Tmax: 1.5-2 hours 1, 2
- Half-life: Approximately 6 hours 1
- Dosing frequency: Typically requires twice-daily administration
Clinical Implications
The extended-release formulation allows for once-daily evening dosing, which may help mitigate daytime sedation—a common side effect 4. The slower absorption profile results in approximately 13% lower peak concentrations (Cmax) compared to equivalent doses of immediate-release quetiapine given twice daily, while maintaining similar total daily exposure (AUC) 2.
Food Effects
A high-fat meal significantly increases both the rate and extent of absorption of Seroquel XR, increasing AUC and Cmax 5, 4. However, a light meal has no significant effect 4. This is an important consideration for consistent dosing.
Receptor Occupancy Profile
The extended-release formulation exhibits less pronounced D2 receptor occupancy peaks, with receptor occupancy levels remaining elevated for longer periods compared to immediate-release quetiapine 4. This may contribute to improved tolerability, particularly regarding sedation intensity in the first hours after administration 4.